Drugs / Anti-MUC1 vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02544880 | Apr 2016 → Jun 2019 | head and neck squamous cell carcinoma | Donald T. Weed, MD, FACS | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-MUC1 vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02544880 ↗ |
| Modality | Vaccine | “anti-tumor vaccine MUC1/polyICLC” PMID 31214178 ↗ May 2019 |
| Route | Intramuscular | “300 uL Anti-MUC1 vaccine will be administered intramuscularly in the right upper limb.” NCT02544880 ↗ |